Fulcrum Therapeutics announced it discontinued its sickle cell disease drug program due to FDA concerns about cancer risks linked to similar drugs. This led to a 51% drop in its stock price, prompting Kaplan Fox & Kilsheimer LLP to investigate potential securities violations. Investors who suffered losses are encouraged to contact the law firm. The investigation highlights regulatory challenges for treatments targeting the PRC2 complex.
Gossamer Bio stands out in the biotech sector by generating a Return on Invested Capital (ROIC) of 697.21%, vastly exceeding its Weighted Average Cost of Capital (WACC) of 6.57%. This results in an ROIC to WACC ratio of 106.17, meaning the company cr...
Mercury Systems, a defense technology firm, is expected to exceed its upcoming earnings estimates, driven by increased global defense spending due to geopolitical tensions. The company supports numerous defense programs and contractors, benefiting fr...
ACCO Brands Corporation, known for products like Five Star and Swingline, is showing promising growth despite a recent 3% dip in its stock price over 10 days. The stock has gained about 5.2% over the past month, suggesting positive momentum. Analysts...
Amer Sports reported a strong Q1 2026 with revenue up 32% and adjusted EBITDA rising over 30% to $432 million, prompting an upward revision of its full-year financial guidance. Key brands like Arc'teryx and Salomon drove this growth across all market...
Argenx's stock surged 16.66% following positive Phase III ALKIVIA trial results for its autoimmune drug Vyvgart Hytrulo, showing significant efficacy in treating autoimmune myositis. Analyst firm William Blair reaffirmed an 'Outperform' rating, refle...
